Astellas evaluates Eyam Health's Gemini RNA platform

Eyam Health said Astellas Pharma is evaluating its Gemini self-amplifying RNA platform for potential use in mRNA therapeutics. The work centers on whether Gemini can extend protein expression and reduce how often patients need repeat dosing.

Why it matters: - Eyam Health's Gemini platform is built to sustain therapeutic protein expression longer than conventional mRNA approaches. - Longer expression could reduce repeat dosing, which is a major limitation of current protein and RNA medicines. - Astellas' evaluation gives Eyam a potential path to broader use in mRNA therapeutics.

What happened: - Eyam Health announced that Astellas Pharma Inc. is evaluating Eyam's Gemini self-amplifying RNA platform for potential applications in mRNA therapeutics. - The announcement was made Nov. 2, 2026, in Vancouver, British Columbia. - Eyam said the evaluation focuses on Gemini's potential to support durable expression of therapeutic proteins.

The details: - Therapeutic proteins are often delivered as manufactured recombinant protein or as conventional mRNA. - Conventional mRNA typically produces protein for a day or two before the message degrades. - Eyam says Gemini is designed to extend protein expression well beyond administration. - Ryan M. Thomas, Eyam Health CEO, said the evaluation offers an opportunity to extend the company's position in mRNA therapeutics. - Dr. Wilf Jefferies, Eyam Health CSO, said saRNA can copy itself inside the cell, which helps maintain elevated protein production after a single administration. - Jefferies said saRNA differs from viral delivery because it introduces no viral particle and does not integrate into the genome. - Eyam said its platforms are designed to be used with partners that bring therapeutic and development expertise. - Eyam's Gemini platform is designed to enable durable, redosable expression of therapeutic proteins, including antibodies, enzymes and vaccine antigens. - Eyam's Jennerator platform is designed to accelerate the design of optimized biologics. - Eyam was founded in 2020 and is headquartered in Vancouver, BC. - Eyam says its pipeline spans infectious disease, companion animal health and oncology. - More information is available at the company's website. - Eyam also listed its social media presence at its LinkedIn page.

Between the lines: - The evaluation signals outside interest in whether self-amplifying RNA can solve one of the field's biggest problems: short-lived expression. - Eyam is positioning Gemini as a platform technology rather than a single product candidate. - The release frames Astellas as a validation partner, but no deal terms, timeline or study design were disclosed.

What's next: - Eyam said the objective is to see whether the study supports further development of Gemini in mRNA therapeutics. - The company said any future progress will depend on research results, funding, partnerships and regulatory requirements. - The release did not say when Astellas will finish the evaluation or whether the work could lead to a broader collaboration.

The bottom line: - Astellas is testing whether Eyam Health's Gemini platform can make RNA-based therapeutics last longer and work with less frequent dosing.